In this regard, G2A may be a novel target for breast cancer, and G2A-inhibitors may interrupt the lactate-G2A-PPARγ-axis and may shift TAMs towards a proinflammatory phenotype in which they can attack tumor cells. This evidence concerns the gene PPARG and neoplasm.